|
Abstract
In 2003, the spread of SARS brought opportunities for China's health product industry, which was in recession for years. Anything that can improve health conditions represented hot selling, even out of stock. Sales revenue of health product industry increased to ￥30 billion yuan in 2003 from ￥20 billion yuan in 2002, up by 50 percent; More important, consumers' consciousness of health care has been wakened. Along with "Health Food Association of China (HFAC)" was canceled and “China Health Technology Association” changed to "China Health Care Association", consumers more trust in health products.
Amway achieved prominent sales performance in China in 2003, with annual sales revenue of ￥4.2 billion yuan. Meanwhile, due to the forthcoming of China's direct-selling law, Nuskin indicated itself would enter into Chinese health product market, challenge Amway directly.
Based on the statistics from National Statistic Bureau, China Health Product Association, China Economic Information Center, China Commercial Information Center, China Medical Healthcare Association, China Economic Monitoring Center, Ministry of Health and other 500 newspapers and magazines, the report presents an in-depth analysis on China's health product sector and its segmented markets, consumption status and competition pattern; it also presents a forecast on China's health product development trends.
Table of Content
Part 1 Analysis on the development of China's health product sector
Chapter One: Definition and classification of health products
Chapter Two: Development of China's health product sector
2.1. Three upgrading periods
2.2. Six development stages
2.3. Market status
2.4. Analysis on major economic indicators
2.5. Retrospect of year 2003
2.6. Prospects of health product sector
Part 2 Development status of global health product industry
Chapter Three: Development summary of global health product industry
Chapter Four: Development of the health product industry in major countries/regions
Chapter Five: Development trends of global health product industry
Chapter Six: R&D analysis
Part 3 Market segmentation analysis of China's health product industry
Chapter Seven: Calcium products
7.1. Markey summary
7.2. Consumer analysis
7.3. Competitive pattern
7.4. Wyeth-Whitehall Pharmaceutical Co., Ltd.
7.5. Shenzhen Neptunus Bioengineering Co., Ltd
7.6. Harbin Pharm. Group sixth
7.7. Beijing Jinde
7.8. Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd.
7.9. Gaitianli
7.10. Jiansu Longniqi Group Co., Ltd
Chapter Eight: Vitamin products
8.1. Market development
8.2. Consumer analysis
8.3. Hangzhou Minsheng Pharmaceutical Group Co., Ltd.
8.4. Shanghai Goldpartner Biotech Co,. Ltd
8.5. Shanghai Squibb
8.6. Latest developments
8.7. Forecasts
Chapter Nine: weight-losing products
9.1. Summary
9.2. Market status in the last 2 years
9.3. Consumer analysis
9.4. Problems
9.5. Competition analysis
9.6. Qumei Co., Ltd
9.7. Nanjing Changao Co., Ltd
9.8. Shantou Dayinxiang Co., Ltd
9.9. Prospects
Chapter Ten: Anti-aging products
10.1. Consumer analysis
10.2. Competition analysis
10.3. Jiankangyuan Group Co., Ltd
10.4. Yunnan Yunhai Group Co., Ltd
10.5. Guangzhou Yipintang Biotech Co., Ltd
10.6. Prospects
Chapter Eleven: Products for enrichment of brain products
11.1. Summary
11.2. Market characteristics
11.3. HK Kangful International Co., Ltd
11.4. Naolingtong
Chapter Tweleve: Products for enrichment of Blood
12.1. Summary of the market development
12.2. Competition analysis
12.3. Dong' E Ejiao Group Co., Ltd
12.4. Investment suggestions
Chapter Thirteen: Products for enrichment of Digestion & Stomach
13.1. Market development
13.2. Consumer analysis
13.3. Shanghai Jiao Da Onlly Co., Ltd.
Chapter Fourteen: Immunity products
14.1. Market status
14.2. Ginseng market
14.3. Shenzhen Wanji Pharmaceutical Co., Ltd.
Part 4. Sizeable enterprises
Chapter Fifteen: Chinese sizeable leading enterprises
15.1. Qindao Jiante BiotechCo., Ltd
15.2. Chengqing Taiji Group
Chapter Sixteen: Global sizeable leading enterprises
16.1. Amway America
16.2. Amway China
16.3. Roche Group
16.4. Roche China
Part 5. Marketing strategy of major brands
Chapter Seventeen: Review on the marketing strategies of major brands
17.1. Taiyangshen
17.2. Sanzhu
17.3. Naobaijin
17.4. Hongtao K
Chapter Eightteen: Marketing strategies of health product industry in China
18.1. Concept strategy
18.2. Ads Strategy
18.3. Brand strategy
Chapter Nineteen: Successful cases
19.1. Naobaijin
19.2. Alashancongrong
Part 6 Trends and investment suggestions
Chapter Twenty: Development trends of China's health product industry
20.1. Nutrition status of Chinese people
20.2. Development of internal factors
20.3. Development of external factors
20.4. Prospects
20.5. Forecasts on the demand
Chapter 21 Investment analysis of China's health product industry
21.1. SWOT analysis
21.2. Recommendations on the investment orientation
21.3. Market strategy
21.4. Successful service marketing modes
21.5. Marketing development trends
21.6. Position and problems of conference marketing
Selected Figures
Development in different stages
Variety in sales revenue
Investment structure of China's health product industry, 2003
Calcium consumption of different age groups, by month
Sales Revenue of principle businesses for HAIWANG GROUP CO., LTD, 2001-2004
Shareholders of HAYAO and its principle products
Sales volume of 21JINWEITA
Monthly rank of weight -losing products by sales revenue
Monthly rank of anti-aging products by sales revenue
|
Published time |
Pages |
Publisher |
Price |
|
Nov/2004 |
280 |
ResearchInchina |
$1800 (PDF) |
|
$1650 (Hard Copy) |
|
您现在的位置： 
